Clinical trial / 2012
A 9-month curcumin intervention prevented progression to type 2 diabetes and improved β-cell function in people with prediabetes.
A randomized, double-blinded, placebo-controlled trial assigned 240 prediabetic subjects to receive curcumin or placebo capsules for 9 months. After 9 months, 16.4% of subjects in the placebo group were diagnosed with type 2 diabetes mellitus, compared to none in the curcumin-treated group. The curcumin group also demonstrated significantly higher HOMA-β (61.58 vs. 48.72; P < 0.01), lower C-peptide (1.7 vs. 2.17; P < 0.05), lower HOMA-IR (3.22 vs. 4.04; P < 0.001), and higher adiponectin (22.46 vs. 18.45; P < 0.05) compared to placebo, with very minor adverse effects reported.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 240 subjects with criteria of prediabetes
- What was measured
- Progression to type 2 diabetes, β-cell function (HOMA-β, C-peptide, proinsulin/insulin), HOMA-IR, and adiponectin
THE PAPER
Curcumin extract for prevention of type 2 diabetes.
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Diabetes Care, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.